Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

Completed · Not applicable

Conditions studied: Metachromatic Leukodystrophy

In brief

Objectives/Purpose: To determine the safety and efficacy of a Vitamin K (Vit K) antagonist (warfarin) in treating Metachromatic Leukodystrophy (MLD).

Key facts

Study ID

NCT00683189

Run by

The Cooper Health System

People needed

10

Starts

2007-06-01

Expected to finish

2008-05-01

Last updated by the study team

2011-03-21

Who can join

Age: 1 and older, up to 10. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children with MLD, 1 to 10 years of age who have received and failed bone marrow transplantation or are excluded from the treatment due to delayed diagnosis or any other reasons.

You may not qualify if…

• Any Children with MLD who are eligible for and might receive ABMT.
• Any Children with MLD who suffer with a bleeding disorder, moderate to severe anemia or any other hematological disorders.
• Any contraindications systemic for anti-coagulation

Where it is running

• Cooper University Hospital — Camden, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.